Existing backer Gilead Sciences returned for a series B round that boosted the kidney disease therapy developer's total funding to $160m.
US-based kidney disease medication developer Goldfinch Bio, a closed an oversubscribed $100m series B round yesterday led by investment adviser Eventide Asset Management and backed by biopharmaceutical company Gilead Sciences.
Wellington Management Company, Ally Bridge Group, Casdin Capital, Irving Investors, Yonjin Capital and Schroeder Adveq took part in the round, along with funds and accounts managed by BlackRock, and undisclosed additional institutional investors.
Goldfinch is working on kidney disease treatments intended to avoid the toxicity and non-specificity prevalent with existing…
